Ventrus Biosciences Down Over 50% on After Announcing Iferanserin Phase 3 Results
Ventrus Biosciences (NASDAQ: VTUS) is trading sgnificantly lower on the session after it announced that the results from pivotal phase 3 trial of Iferanserin (VEN 309) did not meet endpoints. Ventrus Biosciences said it does not have immediate plans to continue development of VEN 309.
Russell H. Ellison, M.D., M.Sc., Chairman and Chief Executive Officer of Ventrus Biosciences said, "We would like to thank both investigators and patients for their support and participation in this study and in the VEN 309 program. The outcome of our Phase 3 study comes as a surprise and a disappointment, particularly given the strong evidence of activity in our Phase 2 randomized study."
Ventrus Biosciences $5.68, a loss of $6.58 or 53.69%.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.